Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • 99mTc-MIP-1404: Phase IIa started

    Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Tarrytown, N.Y. Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan Product: 99mTc-MIP-1404 (1404, F-1311) (formerly 99mTc-trofolostat) Business: Diagnostic Molecular target:…

    Published on 4/27/2015
  • DermaPro: Completed Phase III enrollment

    Centaur Pharmaceuticals Pvt. Ltd., Mumbai, India CytoTools AG (Xetra:T5O), Darmstadt, Germany Product: DermaPro (CLO5) Business: Dermatology Molecular target: NA Description: Derivative of dichloric acid applied by a …

    Published on 4/27/2015
  • HSV-2 vaccine: Phase II started

    Admedus Ltd. (ASX:AHZ), Perth, Australia Product: HSV-2 vaccine Business: Infectious Molecular target: NA Description: Herpes simplex virus type 2 (HSV-2) vaccine Indication: Vaccinate against herpes simplex virus type …

    Published on 4/27/2015
  • I-131-CLR1404: Phase I started

    Cellectar Biosciences Inc. (NASDAQ:CLRB), Madison, Wis. Product: I-131-CLR1404 (HOT) Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) Description: Iodine-radiolabeled small molecule phosphoinositide 3…

    Published on 4/27/2015
  • LIPO-202: Phase III started

    Neothetics Inc. (NASDAQ:NEOT), San Diego, Calif. Product: LIPO-202 Business: Other Molecular target: Adrenergic receptor beta 2 (ADRB2) Description: Subcutaneous formulation of salmeterol, a long-acting adrenergic …

    Published on 4/27/2015
  • Livatag doxorubicin: Phase III ongoing

    Onxeo S.A. (Euronext:ONXEO; CSE:ONXEO), Paris, France Product: Livatag doxorubicin (Livatag doxorubicin Transdrug) (BA-003) Business: Cancer Molecular target: DNA Description: Nanoparticle formulation of doxorubicin …

    Published on 4/27/2015
  • Lutathera: Completed Phase III enrollment

    Advanced Accelerator Applications S.A., Saint Genis Pouilly, France Covidien plc (NYSE:COV), Dublin, Ireland Product: Lutathera, 177Lu-DOTA0-Tyr3-Octreotate Business: Cancer Molecular target: Somatostatin receptor …

    Published on 4/27/2015
  • NS2: Phase II started

    Aldeyra Therapeutics Inc. (NASDAQ:ALDX), Burlington, Mass. Product: NS2 Business: Ophthalmic Molecular target: NA Description: Small molecule that traps and allows for the disposal of free aldehydes Indication: Treat …

    Published on 4/27/2015
  • OMS721: Compassionate use program started

    Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS721 Business: Hematology Molecular target: Mannan-binding lectin-associated serine protease-2 (MASP-2) Description: Human mAb against mannan-binding lectin-…

    Published on 4/27/2015
  • Pan-influenza A mAb: Phase I started

    Humabs BioMed S.A., Bellinzona, Switzerland AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Pan-influenza A mAb (MEDI8852) Business: Infectious Molecular target: NA Description: IgG1 kappa mAb that binds the …

    Published on 4/27/2015
  • Ponesimod: Phase II started

    Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Product: Ponesimod (ACT-128800) Business: Transplant Molecular target: Sphingosine 1-phosphate receptor 1 (S1PR1) (S1P1) (EDG1) Description: Sphingosine-1-phosphate …

    Published on 4/27/2015
  • Ponesimod: Phase III started

    Actelion Ltd. (SIX:ATLN), Allschwil, Switzerland Product: Ponesimod (ACT-128800) Business: Autoimmune Molecular target: Sphingosine 1-phosphate receptor 1 (S1PR1) (S1P1) (EDG1) Description: Sphingosine-1-phosphate …

    Published on 4/27/2015
  • PV-10: Phase III started

    Provectus Biopharmaceuticals Inc. (NYSE-M:PVCT), Knoxville, Tenn. Product: PV-10 Business: Cancer Molecular target: Not available Description: Sterile injection containing 10% rose bengal disodium Indication: Treat …

    Published on 4/27/2015
  • RVSV-EBOV: Phase II/III started

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: RVSV-EBOV, VSV-ZEBOV, rVSV-ZEBOV-GP, VSV-EBOV Business: Infectious Molecular target: NA Description: …

    Published on 4/27/2015
  • subcutaneous ALX-0061: Phase IIb started

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: subcutaneous ALX-0061 Business: Autoimmune Molecular target: Interleukin-6 (IL-6) receptor (CD126) Description: Subcutaneous …

    Published on 4/27/2015
  • Sustol: Completed Phase III enrollment

    Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: Sustol (APF530) Business: Gastrointestinal Molecular target: Serotonin (5-HT3) receptor Description: Long-acting formulation of granisetron, a …

    Published on 4/27/2015
  • ADXS-HPV: Phase I/II started

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Product: ADXS-HPV (ADXS11-001) (formerly Lovaxin C) Business: Cancer Molecular target: NA Description: Live Listeria …

    Published on 4/20/2015
  • ARC-520: Phase IIb start

    Arrowhead Research Corp. (NASDAQ:ARWR), Pasadena, Calif. Product: ARC-520 Business: Infectious Molecular target: NA Description: Short interfering RNAs targeting 2 regions of the HBV genome conjugated to N-…

    Published on 4/20/2015
  • CTX-4430: Phase II started

    Celtaxsys Inc., Atlanta, Ga. Product: CTX-4430 (formerly EP-501) Business: Dermatology Molecular target: Leukotriene A4 hydrolase (LTA4H) Description: Leukotriene A4 hydrolase (LTA4H) inhibitor Indication: Treat …

    Published on 4/20/2015
  • D-Ivacaftor: Phase I started

    Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass. Product: D-Ivacaftor (C-10358) Business: Pulmonary Molecular target: NA Description: Oral deuterium-modified ivacaftor, a potentiator of cystic fibrosis …

    Published on 4/20/2015
  • D-Ivacaftor: Phase I started

    Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass. Product: D-Ivacaftor (C-10355) Business: Pulmonary Molecular target: NA Description: Oral deuterium-modified ivacaftor, a potentiator of cystic fibrosis …

    Published on 4/20/2015
  • Dexmedetomidine: Phase II ongoing

    Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Product: Dexmedetomidine (Dex-IN) Business: Neurology Molecular target: Adrenergic receptor alpha 2 (ADRA2) Description: Intranasal formulation of dexmedetomidine, an …

    Published on 4/20/2015
  • DRM01: Phase IIb started

    Dermira Inc. (NASDAQ:DERM), Menlo Park, Calif. Product: DRM01 (formerly VAL-001, QLT91382) Business: Dermatology Molecular target: Acetyl-Coenzyme A carboxylase (ACAC) (ACC) Description: Topical prodrug of an acetyl-…

    Published on 4/20/2015
  • Gevokizumab: Phase II started

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Servier, Neuilly-sur-Seine, France Product: Gevokizumab (S 78989, XOMA 052) Business: Renal Molecular target: Interleukin-1 (IL-1) beta Description: Humanized IgG2 mAb against …

    Published on 4/20/2015
  • Listeria monocytogenes/PSA: Phase I/II started

    Advaxis Inc. (NASDAQ:ADXS), Princeton, N.J. Product: Listeria monocytogenes/PSA (Lm-LLO-PSA) vaccine (ADXS-PSA) (formerly ADXS31-142) Business: Cancer Molecular target: Prostate-specific antigen (KLK3) (PSA) Description…

    Published on 4/20/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993